Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579085 | 0.91 | SCN2A (0.47) | SCN2ASCN10ANAMPTRETCYP3A4 | |
| SCHEMBL3578235 | 0.90 | SCN2A (0.45) | SCN2ASCN10ANAMPTCYP3A4CYP2C9 | |
| SCHEMBL13500282 | 0.87 | SCN2A (0.55) | SCN2ASCN10ANAMPTPIK3CACYP3A4 | |
| SCHEMBL3576886 | 0.83 | SCN2A (0.41) | SCN2ASCN10ANAMPTPIK3CACYP3A4 | |
| SCHEMBL3586017 | 0.83 | SCN2A (0.41) | SCN2ASCN10ANAMPTPIK3CACYP3A4 | |
| SCHEMBL3576468 | 0.81 | TEK (0.49) | SCN2ASCN10ANAMPTCYP3A4CYP2C9 | |
| SCHEMBL3580192 | 0.81 | LCK (0.43) | NAMPTCYP3A4CYP2C9POLB | |
| SCHEMBL3576068 | 0.81 | NPC1 (0.48) | SCN2ASCN10ANAMPTRETCYP2C9 | |
| SCHEMBL13500262 | 0.80 | SCN2A (0.47) | SCN2ASCN10ANAMPTPIK3CACYP3A4 | |
| SCHEMBL3582962 | 0.80 | BTK (0.43) | SCN2ASCN10ANAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | SCN2A 4543/4885SCN10A 4171/4885NAMPT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.